Thymalin
A thymus-derived peptide preparation used clinically in Russia and some CIS countries as an immune modulator. It has a long regional history of use but is not FDA-approved, and independent Western evidence is limited.
Quick take
- What it is: a peptide preparation extracted from the thymus gland (originally of calves), used to influence immune function.
- What people use it for: supporting or rebalancing immune responses, including during illness and recovery.
- What we actually know: it has decades of clinical use in Russia and CIS countries, but high-quality, independent Western trials are scarce.
- Status: not FDA-approved; used as a registered medicine mainly within Russia and some neighbouring countries.
What it is
Thymalin is a peptide preparation derived from the thymus gland (historically from calf thymus), developed and used as an immune-modulating medicine primarily in the former Soviet Union and, later, Russia and some CIS countries.1 Rather than being a single defined molecule like Thymosin Alpha-1, it is described as a fraction of thymic polypeptides.
Its long regional history of clinical use sits alongside a relatively thin base of independent international evidence — a contrast that is the most important thing to understand about it.
How it works
Thymalin is thought to act as an immune modulator, influencing the maturation and balance of T cells and helping regulate immune responses — in keeping with the thymus’s natural role in training the immune system.2 Proponents also describe broader “bioregulatory” and anti-ageing effects, which are far less well established.
Because it is a tissue-derived preparation, its exact composition and activity can be harder to characterise than a single synthetic peptide.
What the evidence shows
Laboratory and animal studies
Experimental work has reported effects of thymic peptide preparations on immune-cell function and on markers relevant to ageing.2 Much of this research comes from a limited number of groups and has not been broadly replicated under modern Western standards.
Human studies
Human evidence consists largely of clinical reports and studies from Russia and CIS countries, where Thymalin has been used for decades in immune-related and recovery settings.3 Independent, large, rigorously controlled trials published in major international journals are scarce. The honest summary is a long regional track record but limited independent confirmation.
Dosages reported in the literature
Informational only. The figures below describe doses reported in regional clinical use. They are not a recommendation or a prescription. Appropriate use, if any, should be determined by a qualified healthcare professional who can account for your individual situation and local regulations.
| Setting | Route | Reported range |
|---|---|---|
| Regional clinical use | Intramuscular | Reported in low milligram amounts per day, in short courses |
| Anecdotal use | Injection | Varies between sources; not standardised internationally |
No range here should be read as established as safe or effective outside the regulated settings where the product is actually approved.
Safety & side effects
Within its regional clinical use, Thymalin is generally described as well tolerated, with injection-site reactions among the more common issues.3 However, robust long-term safety data from independent trials are limited, and as an immune-active, tissue-derived product, medical supervision is especially important.
Outside regulated supply, products sold as “Thymalin” raise the usual concerns about identity, purity and dose accuracy.
Legal & regulatory status
Thymalin is not approved by the FDA and is not a recognised medicine in most Western countries. It has been used as a registered medicine mainly in Russia and some CIS countries.4 As with other regionally used peptides, approval in one jurisdiction does not imply approval elsewhere. Rules differ by country and change over time.
References
- Khavinson VKh, Linkova NS, Chalisova NI, Ivko OM. The Use of Thymalin for Immunocorrection and Molecular Aspects of Biological Activity. Biology Bulletin Reviews. 2021;11(4):377-382. doi:10.1134/S2079086421040046. (PMC8365293) [doi:10.1134/S2079086421040046]
- Morozov VG, Khavinson VK. Natural and synthetic thymic peptides as therapeutics for immune dysfunction. Int J Immunopharmacol. 1997;19(9-10):501-505. doi:10.1016/s0192-0561(97)00058-1. PMID:9637345 [PMID 9637345, doi:10.1016/s0192-0561(97)00058-1]
- Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-240. PMID:14523363 [PMID 14523363]
- U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs database (no approved product for ‘thymalin’). Accessed June 2026. https://www.accessdata.fda.gov/scripts/cder/daf/ . Russian Federation registration: State Register of Medicines (Gosudarstvennyy reestr lekarstvennykh sredstv), Thymalin registration No. LS-000267 (Ministry of Health of the Russian Federation). https://grls.rosminzdrav.ru/ [accessdata.fda.gov, grls.rosminzdrav.ru] (source identified; pending manual verification)